The primary endpoint was the probability that the extended pulse and taper regimen would be superior in preventing recurrence ...
Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today ...
A tailored approach of vitamin D3 supplementation in patients who have suffered a heart attack significantly reduces their risk of a second heart attack, a new ...
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. This is an ...
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L ...
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone ...
A team of University of Michigan investigators reported that their multimodal, chronic disease self-management support program for people living with glaucoma, SEE, was linked to an approximate 20% ...
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...
The May 29, 2026 PDUFA targets pediatric approval of Afrezza for type 1 or type 2 diabetes, leveraging INHALE-1 outcomes versus rapid-acting analogs plus basal insulin. INHALE-1 was open-label and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results